1.
Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiologica...
by Yusuf, Salim, Prof
The Lancet (British edition), 2011, Vol.378 (9798), p.1231-1243
2.
Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study
by Swedberg, Karl, Prof
The Lancet (British edition), 2010, Vol.376 (9744), p.875-885
3.
Medication adherence: A call for action
by Bosworth, Hayden B., PhD
The American heart journal, 2011, Vol.162 (3), p.412-424
4.
Quality of Care and In-Hospital Outcomes in Patients With Coronary Heart Disease in Rural and Urban Hospitals (from Get With the Guidelines–Coronary Artery Disease Program)
by Ambardekar, Amrut V., MD
The American journal of cardiology, 2010, Vol.105 (2), p.139-143
5.
Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial
by Böhm, Michael, Prof
The Lancet (British edition), 2010, Vol.376 (9744), p.886-894
6.
Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study da...
by Khatib, Rasha, PhD
The Lancet (British edition), 2016, Vol.387 (10013), p.61-69
7.
Metabolic syndrome update
by Grundy, Scott M., MD, PhD
Trends in cardiovascular medicine, 2015, Vol.26 (4), p.364-373
8.
Eph Receptors and Ephrins: Therapeutic Opportunities
by Barquilla, Antonio
Annual review of pharmacology and toxicology, 2015-01-06, Vol.55 (1), p.465-487
9.
Trends in the epidemiology of cardiovascular disease in the UK
by Bhatnagar, Prachi
Heart (British Cardiac Society), 2016-12, Vol.102 (24), p.1945-1952
10.
Obesity, inflammation, and atherosclerosis
by Libby, Peter
Nature reviews cardiology, 2009-06, Vol.6 (6), p.399-409
11.
Reducing myocardial infarct size: challenges and future opportunities
by Bulluck, Heerajnarain
Heart, 2016-03, Vol.102 (5), p.341-348
12.
Invasive versus conservative strategy in patients aged 80 years or older with non-ST-elevation myocardial infarction or unstable angina pectoris (After Eighty study): an open-label...
by Tegn, Nicolai, MD
The Lancet (British edition), 2016, Vol.387 (10023), p.1057-1065
13.
Diagnosis and treatment of pericarditis
by Imazio, Massimo
Heart (British Cardiac Society), 2015-07, Vol.101 (14), p.1159-1168
14.
Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous...
by Shaw, Leslee J., PhD
The American heart journal, 2012, Vol.164 (2), p.243-250
15.
Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from efficacy of vasopressin ant...
by O'Connor, Christopher M., MD
The American heart journal, 2010, Vol.159 (5), p.841-849.e1
16.
Generic versus brand-name drugs used in cardiovascular diseases
by Manzoli, Lamberto
European journal of epidemiology, 2016-01-01, Vol.31 (4), p.351-368
17.
Atherosclerosis and interferon-γ: New insights and therapeutic targets
by Voloshyna, Iryna
Trends in cardiovascular medicine, 2013, Vol.24 (1), p.45-51
18.
Prevalence of comorbidities in COPD patients by disease severity in a German population
by Greulich, Timm
Respiratory medicine, 2017-11, Vol.132, p.132-138
19.
Serelaxin and acute heart failure
by Tietjens, Jeremy
Heart (British Cardiac Society), 2016-01, Vol.102 (2), p.95-99
20.
Comparison of Percutaneous Mitral Valve Repair Versus Conservative Treatment in Severe Functional Mitral Regurgitation
by Giannini, Cristina, MD, PhD
The American journal of cardiology, 2016, Vol.117 (2), p.271-277
